Overactive Bladder
📧 Sign up to get email alerts when something new happens for Overactive Bladder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2017-10-03FDA Approved: FESOTERODINE FUMARATE — Original Application (Zydus Pharmaceuticals USA Inc.)
FDA approved the original abbreviated new drug application (ANDA) for fesoterodine fumarate (generic), manufactured by Zydus Pharmaceuticals…
-
CLINICAL_TRIALS research · 2017-09-01Clinical Trial Update: The Effect of an Additional Stress Incontinence Procedure on Overactive Bladder During Pelvic Organ Prolapse Repair
This clinical trial update reports on the completed study evaluating whether adding a stress incontinence procedure influences overactive bl…
-
CLINICAL_TRIALS research · 2017-08-28Clinical Trial Update: Efficacy and Safety of Electroacupuncture and Acupuncture in Postmenopausal Women With Overactive Bladder [NA]
This clinical trial update evaluates the efficacy and safety of electroacupuncture and acupuncture in postmenopausal women with overactive b…
-
CLINICAL_TRIALS trial_result · 2017-08-21Clinical Trial Update: Effects of Transcutaneous and Percutaneous PTNS on Idiopathic OAB [NA]
A completed clinical trial evaluating transcutaneous and percutaneous PTNS for idiopathic overactive bladder (with urge incontinence) has fi…
-
CLINICAL_TRIALS trial_result · 2017-08-01Clinical Trial Update: Urinary Biomarkers For Objective Measurement Of InterStim® Response In Over Active Bladder (OAB) Patients.
An update on a completed clinical trial investigating urinary biomarkers to objectively measure responses to InterStim sacral neuromodulatio…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA label_change · 2017-07-28FDA Approved: MYRBETRIQ — Supplemental Application (Astellas Pharma US, Inc.)
FDA approved a supplemental application for MYRBETRIQ (mirabegron) submitted by Astellas Pharma US, updating the product labeling.
-
FDA approval · 2017-07-28FDA Approved: DARIFENACIN — Original Application (Macleods Pharmaceuticals Limited)
FDA approved the original application for darifenacin from Macleods Pharmaceuticals Limited, marking the approval of a generic formulation o…
-
CLINICAL_TRIALS research · 2017-07-11Clinical Trial Update: Comparison of Craniosacral Therapy vs Pelvic Floor Physical Therapy [NA]
This clinical trial update compares craniosacral therapy with pelvic floor physical therapy for MS-related bladder dysfunction, including ur…
-
FDA approval · 2017-06-26FDA Approved: OXYBUTYNIN — Original Application (Zydus Pharmaceuticals USA Inc.)
FDA approved the original ANDA for oxybutynin from Zydus Pharmaceuticals USA Inc., authorizing a generic version of the drug.
-
CLINICAL_TRIALS withdrawal · 2017-06-16Clinical Trial Update: Safety and Efficacy Study of Intravesical Instillations of BotuGelTM, Slow Release RTGel Based Botox® Formulations, in Idiopathic OAB Patients With Urinary Incontinence ("INTIMO2") [Phase 1, Phase 2]
A phase 1/2 clinical trial evaluating intravesical instillations of BotuGel and slow-release RTGel-based Botox formulations for idiopathic o…
-
CLINICAL_TRIALS trial_result · 2017-05-31Clinical Trial Update: Overactive Bladder in Elderly Patients- An Early Warning of Coronary Artery Disease
A completed clinical trial update examining whether overactive bladder in elderly patients may act as an early indicator of coronary artery …
-
CLINICAL_TRIALS trial_result · 2017-05-25Clinical Trial Update: Combined Behavioral and Drug Treatment of Overactive Bladder in Men [Phase 2, Phase 3]
This report summarizes a completed Phase 2/Phase 3 clinical trial evaluating a combined behavioral therapy and drug treatment for overactive…
-
CLINICAL_TRIALS trial_result · 2017-05-18Clinical Trial Update: Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder [Phase 4]
A Phase 4 study examines the efficacy, safety, and tolerability of darifenacin in patients over 65 with overactive bladder.
-
CLINICAL_TRIALS research · 2017-05-17Clinical Trial Update: Clinical and Urodynamic Predictors for Sacral Neuromodulation Outcomes in Overactive Bladder
An update on a study evaluating clinical and urodynamic predictors of sacral neuromodulation outcomes for overactive bladder.
-
CLINICAL_TRIALS withdrawal · 2017-05-16Clinical Trial Update: Overactive Bladder Posterior Tibial Implantable MIcro STimulator - 1 [NA]
A clinical trial evaluating a posterior tibial implantable micro-stimulator for overactive bladder has been withdrawn.
-
CLINICAL_TRIALS research · 2017-05-10Clinical Trial Update: Audiovisual Stimulus During Urodynamics [NA]
Update on a clinical trial investigating audiovisual stimulus during urodynamics for Overactive Bladder. The study status is completed.
-
CLINICAL_TRIALS trial_result · 2017-04-28Clinical Trial Update: Pilot Study: Is Overactive Bladder Caused by Subacute Urinary Tract Infections?
A pilot study investigated whether subacute urinary tract infections contribute to overactive bladder; the study is completed and results we…
-
CLINICAL_TRIALS trial_result · 2017-04-20Clinical Trial Update: Premarin Versus Toviaz for Treatment of Overactive Bladder [Phase 4]
A Phase 4 clinical trial update comparing Premarin (conjugated estrogens) versus Toviaz (fesoterodine) for overactive bladder, sponsored by …
-
CLINICAL_TRIALS trial_result · 2017-04-07Clinical Trial Update: Drug Use Investigation for Toviaz
Clinical trial update for a Pfizer investigation of Toviaz in overactive bladder has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2017-04-07Clinical Trial Update: Transcutaneous Posterior Tibial Nerve Electrostimulation With Low Dose Trospium Chloride in OAB in Females [NA]
This update reports on a completed clinical trial evaluating transcutaneous posterior tibial nerve electrostimulation combined with low-dose…
-
CLINICAL_TRIALS trial_result · 2017-04-05Clinical Trial Update: Time of Effect Onset in Treating Overactive Bladder or Non Obstructive Urinary Retention by Sacral Neuromodulation [NA]
Clinical trial update documenting the time to onset of effect for sacral neuromodulation in treating overactive bladder and nonobstructive u…
-
CLINICAL_TRIALS trial_result · 2017-03-08Clinical Trial Update: Flexibly adding-on Second Antimuscarinic Agent to the First Antimuscarinics for Refractory Overactive Bladder Syndrome [Phase 4]
This clinical trial update reports the completion of a Phase 4 study evaluating the flexible addition of a second antimuscarinic agent to a …
-
CLINICAL_TRIALS trial_result · 2017-02-23Clinical Trial Update: Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan [Phase 3]
A Phase 3 clinical trial of mirabegron in Taiwanese patients with overactive bladder and urinary incontinence has completed.
-
CLINICAL_TRIALS research · 2017-02-23Clinical Trial Update: Effects of Urinary Bladder Hypertrophy on Urge Urine Incontinence After Radical Prostatectomy
A clinical trial update investigating whether urinary bladder hypertrophy influences urge incontinence after radical prostatectomy.
-
FDA approval · 2017-02-17FDA Approved: FESOTERODINE FUMARATE — Original Application (Aurobindo Pharma Limited)
The FDA approved Aurobindo Pharma Limited's generic fesoterodine fumarate through an original ANDA for the treatment of overactive bladder.